364
Views
6
CrossRef citations to date
0
Altmetric
Original Article

Salmeterol/fluticasone through breath-actuated inhaler versus pMDI: a randomized, double-blind, 12 weeks study

, MD, MRCP, FCCP, , MD, DNB, PhD (UK), FCCP, , MD, DETRD, DNB, , MBBS, DTCD, DNB, FCCP, , MD, , MD, , MBBS, TDD, FCCP, , MBBS, DTCD, DNB, FCCP, , MD & , MD show all
Pages 1065-1072 | Received 23 Dec 2014, Accepted 07 May 2015, Published online: 18 Aug 2015
 

Abstract

Objective: Salmeterol/fluticasone combination (SFC) formulated in a breath-actuated inhaler (BAI) overcomes the co-ordination problem associated with the pressurized-metered dose inhaler (pMDIs). Our aim was to compare the efficacy and the safety of SFC given through the BAI versus the conventional pMDI in moderate-to-severe asthmatics. Methods: In this randomized, double-blind, double-dummy, prospective, active-controlled, parallel group, multicenter, 12 weeks study, 150 asthmatics were randomized to receive SFC (25/125 mcg) through either BAI or pMDI. The primary efficacy endpoint was mean change in pre-dose morning PEFR value at 12 weeks and the secondary efficacy endpoints included, mean change in FEV1, pre-bronchodilator FVC, pre-dose morning and evening PEFR, symptom scores at 2, 4, 8, and 12 weeks. Patient preferences for device and safety were also assessed. Results: At 12 weeks, the mean change in pre-dose morning PEFR in BAI and pMDI groups was 50.72 L/min and 48.82 L/min, respectively (p < 0.0001; both groups) and the difference between the two groups was not significant. Both the treatment groups showed a statistically significant improvement in secondary endpoints at all-time points compared with baseline. The usability questionnaire assessment results showed that the BAI device was preferred by 75% of patients as compared with 25% preferring pMDI. SFC in both BAI and pMDI devices was found to be safe and well tolerated. Conclusion: This is the first study to demonstrate that SFC given through the BAI produces comparable efficacy and safety endpoints as pMDI. Additionally, BAI was the preferred inhaler by patients compared to conventional pMDI.

Acknowledgements

The authors would like to thank Dr. Sonali Jadhav and Ms. Pallavi Londhe (Cipla Limited) who helped in conduct of the study. The writing assistance was provided by Mr. Vaibhav Revandkar and Ms. Vaishali Naik (Cipla Limited) in accordance with the CONSORT statement.

Declaration of interest

Dr. Jaideep Gogtay is a permanent employee of Cipla Ltd. Other authors have no conflict of interest. The study was funded by Cipla Ltd.

Supplementary material available online

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.